

#6/16w

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Emil D. KAKKIS

Application No.: 09/993,241

Filed: November 13, 2001

For: **METHODS FOR TREATING
DISEASES CAUSED BY
DEFICIENCIES OF RECOMBINANT
α-L-IDURONIDASE**

Art Unit: 1652

Examiner: Not yet assigned

Attorney Docket No: 00800.0051.CNTR03

RECEIVED
TECH CENTER 1600/2900
02 APR 19 2002 APR 2 2002
AM 29

First Supplemental Information Disclosure Statement

Commissioner for Patents
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

In the examination of the claims of the parent application (Ser. No. 09/439,923), there was only one rejection based on prior art: a 35 U.S.C. §103 rejection of the claims over WO 93/10244. In that application, claims directed to a purified human recombinant α-L-iduronidase having a purity of greater than about 99% have been allowed. In the Notice of Allowability, dated March 21, 2002, the Examiner states:

"... Examiner could not find a reference that either teaches a 99% pure recombinant alpha-L-iduronidase enzyme or even makes it obvious for one skilled in the art to make a 99% pure recombinant alpha-L-iduronidase. Most references in the art teach either pure or "high purity" alpha-L-iduronidase without specifying a per cent purity."

Applicant respectfully submits that the references submitted in the attached Form PTO-1449 do not affect the patentability of the claims in this present application and believes the references are cumulative to those already of record in this and the '923 application. The

RECEIVED

APR 22 2002

TECH CENTER 1600/200

references cited herein are being submitted for the sake of completeness of the record in this application file. For example, U.S. Patent Nos. 6,149,909 and 6,238,662 B1 Scott, *et al.*, are derived from PCT WO 93/10244 to Scott, *et al.* (of record), and are essentially identical in their respective disclosures. Also, Scott, *et al.*, "Human α -L-Iduronidase: cDNA Isolation and Expression", *Proc. Natl. Acad. Sci. USA*, Vol. 88, pp. 9695-9699 (1991) contains essentially the same disclosure as Scott, *et al.*, WO 93/10244. WO 97/10353 discloses the production of α -L-iduronidase in a plant expression system. Scott, *et al.*, "Multiple Polymorphisms Within the α -L-Iduronidase Gene (*IDUA*): Implications for a Role in Modification of MPS-I Disease Phenotype", *Hum. Mol. Genet.* Vol. 2, No. 9, pp. 1471-1473 (1993) disclose the polymorphism of the *IDUA* gene, but do not disclose purifying α -L-iduronidase. Kakkis, *et al.*, "Long-Term and High-Dose Trials of Enzyme Replacement Therapy in the Canine Model of Mucopolysaccharidosis I", *Biochem. Mol. Med.* Vol. 58, No. 2, pp. 156-167 (1996) disclose using recombinant human α -L-iduronidase to treat dogs affected with MPS I. Neufield, *et al.*, "The Mucopolysaccharidoses", The Metabolic Basis of Inherited Disease, McGraw Hill, New York, pp. 1565-1587 (1989) provide an overview of mucopolysaccharidoses and their biochemical basis. Rome, *et al.*, " α -L-Iduronidase for Human Kidney" *Methods in Enzymology*, Vol. 83, pp. 578-582 (1982) disclose the purification of α -L-iduronidase from human kidney to 80% purity. Schuchman, *et al.*, "Human α -L-Iduronidase: Purification and Properties of the High Uptake (Higher Molecular Weight) and the Low Uptake (Processed) Forms", *J. Bio. Chem.*, Vol. 259, No. 5, pp. 3132-3140 (1984) disclose the purification of α -L-iduronidase from human lung, but does not disclose purifying it to a purity of 99% or more. Stoltzfus, *et al.*, "Mucopolysaccharidosis I: cloning and characterization of cDNA encoding canine α -L-Iduronidase", *Am. J. Hum. Genet.*, Vol. 47, No. 3, p. A167, (1990) is an abstract that discloses purification of canine α -L-iduronidase, and contains essentially the same disclosure of Stoltzfus, *et al.* ("Cloning and Characterization of cDNA Encoding Canine α -L-Iduronidase," *J. Biol. Chem.*, Vol. 267, pp. 6570-6575 (1992)) of record. None of the above identified references teach or suggest either (1) purified human recombinant α -L-iduronidase having a purity of greater than about 99%, or (2) that purified human recombinant α -L-iduronidase having a purity of greater than about 99% has an advantage in treating subjects suffering from a disease caused by a

deficiency of α -L-iduronidase.

Therefore, Applicant contends that, in light of the allowability of the claims directed to a purified human recombinant α -L-iduronidase having a purity of greater than about 99% (in the parent application, Ser. No. 09/439,923), the present claims (which include the limitation of "a recombinant α -L-iduronidase enzyme or biologically active fragments or mutant thereof with a purity of equal to or greater than 99%") are also patentable over the prior art.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicant has listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicant reserves the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that had been cited by or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).

Applicant has checked the appropriate boxes below.

- 1. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No statement under 37 C.F.R. § 1.97(e) or fee is required, or
- 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the

merits, but before the mailing date of a Final Rejection or Notice of Allowance, or action that otherwise closes prosecution in the application, and

- a. I hereby state that each item of information contained in this Information Disclosure Statement was cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1), or
- b. I hereby state that no item of information in this Information Disclosure Statement was cited in any communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2), or
- c. Attached is our Check No. _____ in the amount of \$ _____ in payment of the fee under 37 C.F.R. § 1.17(p).

3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but on or before payment of the Issue Fee. Attached is our Check No. _____ in the amount of \$ _____ in payment of the fee under 37 C.F.R. § 1.17(i), and

- a. I hereby state that each item of information contained in this Information Disclosure Statement was cited in any communication from any foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1), or
- b. I hereby state that no item of information in this Information Disclosure Statement was cited in any communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making

reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).

- 4. Relevance of the non-English language document(s) is discussed in the present specification.
- 5. The document(s) was/were cited in a corresponding foreign application. An English language version of the foreign search report is attached for the Examiner's information.
- 6. A concise explanation of the relevance of the non-English language document(s) appears below:
- 7. The Examiner's attention is directed to co-pending U.S. Patent Application No. _____, filed _____, which is directed to related technical subject matter. The identification of this U.S. Patent Application is not to be construed as a waiver of secrecy as to that application now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited application and the art cited therein during examination.

■ 8. Copies of the documents were cited by or submitted to the Office in Application No. 09/711,205, filed November 9, 2000, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 08-3038 referencing docket number 000800.0051.CNUS03.

Respectfully submitted,



Date: April 18, 2002

Albert P. Halluin (Reg. No. 25,227)
Robin C. Chiang (Reg. No. 46,619)

HOWREY SIMON ARNOLD & WHITE, LLP
301 Ravenswood Avenue
Box 34
Menlo Park, CA 94025
(650) 463-8109